HomeVXL • CVE
Vaxil Bio Ltd
Follow
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 57.00K | 72.73% |
Net income | -49.00K | -75.00% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 535.00K | -46.98% |
Total assets | 820.00K | -21.90% |
Total liabilities | 82.00K | -56.84% |
Total equity | 738.00K | — |
Shares outstanding | 136.98M | — |
Price to book | 1.00 | — |
Return on assets | -16.93% | — |
Return on capital | -18.69% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -49.00K | -75.00% |
Cash from operations | -56.00K | -14.29% |
Cash from investing | 0.00 | — |
Cash from financing | — | — |
Net change in cash | -54.00K | 1.82% |
Free cash flow | -40.63K | 0.00% |
Previous close
$0.010
Year range
$0.010 - $0.020
Market cap
1.37M CAD
P/E ratio
-
Dividend yield
-
Primary exchange
CVE
About
Founded
2006
Headquarters
Website
